This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Description, Dosage, Side Effects, Contraindications. Data from EMA, URPL, openFDA and other regulatory sources.
| Semaglutide | Liraglutide | |
|---|---|---|
| Active Substances | semaglutide | LIRAGLUTIDE |
| ATC Code | A10BJ06 | A10BJ02 |
| Form | — | SOLUTION |
| Dosage | — | 18MG/3ML (6MG/ML) |
| Route | — | SUBCUTANEOUS |
| Manufacturer | Novo Nordisk A/S | FRESENIUS KABI USA LLC |
| Indications | Semaglutide is a glucagon-like peptide-1 receptor agonist which is prescribed to treat adult patients with uncontrolled type 2 diabetes along with diet and exercise to improve glucose control. | — |
| Side Effects | Common: Nausea, vomiting, diarrhea, stomach pain, constipation, low blood sugar level Skin: Injection site reactions such as pain, swelling and discomfort Others: Increased level of amylase and lipase, pancreatitis, gallstones , fatigue, taste disturbances, dizziness, abnormal heart rate, allergic reaction |
Semaglutide (INN: semaglutide, ATC A10BJ06) and Liraglutide (INN: LIRAGLUTIDE, ATC A10BJ02) differ in active substance, indications, and safety profile. The table above summarizes the clinical differences from regulatory documents.
Combination safety depends on mechanisms and your health profile. Use our interactions checker and always consult your doctor or pharmacist before combining medications.
Both drugs are approved when used per label. Safety is patient-specific — the better choice depends on your condition, other medications, allergies, and comorbidities. Consult a healthcare professional for personalized advice.
This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
| — |
| Warnings | • Patients should report signs and symptoms of pancreatitis such as severe stomach pain radiating to the back and if present, the treatment with semaglutide injection should be discontinued immediately. • Patients with a previous history of diabetic retinopathy should be monitored to check for the eye-related disease progression. • Treatment with semaglutide injection should be stopped immediately if a severe allergic reaction occurs and patients must be treated appropriately. • Semaglutide injection may cause a serious decrease in the blood sugar level when used along with other antidiabetic drugs, which may require a dose reduction. • Caution is required while using in patients with kidney disease and monitoring kidney function is necessary to avoid the complications. | — |
|---|